Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cellectar Biosciences stock

Learn how to easily invest in Cellectar Biosciences stock.

Cellectar Biosciences Inc is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectar Biosciences employs 12 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Cellectar Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLRB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Cellectar Biosciences stock price (NASDAQ: CLRB)

Use our graph to track the performance of CLRB stocks over time.

Cellectar Biosciences shares at a glance

Information last updated 2022-06-26.
Latest market close$0.40
52-week range$0.34 - $1.32
50-day moving average $0.45
200-day moving average $0.66
Wall St. target price$4.95
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.41

Buy Cellectar Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cellectar Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectar Biosciences price performance over time

Historical closes compared with the close of $0.4 from 2022-06-30

1 week (2022-06-24) -2.44%
1 month (2022-06-02) -4.76%
3 months (2022-04-01) -42.03%
6 months (2021-12-31) -39.39%
1 year (2021-07-02) -67.74%
2 years (2020-07-02) -71.63%
3 years (2019-07-02) 2.18
5 years (2017-06-30) 1.63

Cellectar Biosciences financials

Gross profit TTM $0
Return on assets TTM -34.33%
Return on equity TTM -62.1%
Profit margin 0%
Book value $0.42
Market capitalisation $25.1 million

TTM: trailing 12 months

Cellectar Biosciences share dividends

We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.

Have Cellectar Biosciences's shares ever split?

Cellectar Biosciences's shares were split on a 1:10 basis on 16 July 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.

Cellectar Biosciences share price volatility

Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $0.34 up to $1.32. A popular way to gauge a stock's volatility is its "beta".

CLRB.US volatility(beta: 1.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.5907. This would suggest that Cellectar Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cellectar Biosciences overview

Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. .

Frequently asked questions

What percentage of Cellectar Biosciences is owned by insiders or institutions?
Currently 7.346% of Cellectar Biosciences shares are held by insiders and 24.756% by institutions.
How many people work for Cellectar Biosciences?
Latest data suggests 12 work at Cellectar Biosciences.
When does the fiscal year end for Cellectar Biosciences?
Cellectar Biosciences's fiscal year ends in December.
Where is Cellectar Biosciences based?
Cellectar Biosciences's address is: 100 Campus Drive, Florham Park, NJ, United States, 07932
What is Cellectar Biosciences's ISIN number?
Cellectar Biosciences's international securities identification number is: US15117F5008
What is Cellectar Biosciences's CUSIP number?
Cellectar Biosciences's Committee on Uniform Securities Identification Procedures number is: 15117F104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site